Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company offers BioThrax, an anthrax vaccine; ACAM2000, a Smallpox Vaccine; Raxibacumab, a monoclonal antibody for the treatment and prophylaxis of inhalational anthrax; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. It also provides reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. The company's product candidates include NuThrax, a next generation anthrax vaccine; VLA1601, for the treatment of Zika virus; UNI-FLU, an influenza vaccine; EBX-205, an oral therapeutic to treat acute bacterial skin and skin structure infection; GC-072 for treating Burkholderia pseudomallei infection; EBI-001, a pan respiratory antiviral; FLU-IG (NP025) for the treatment of seasonal influenza; ZIKA-IG (NP024) for Zika infections; and FILOV (NP026) for treating treat hemorrhagic fever caused by Filoviruses. In addition, it provides contract manufacturing services to third-party customers. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone240-631-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$560.87 million
Profitability
Miscellaneous
Employees1,256
OptionableOptionable
Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions
What is Emergent Biosolutions' stock symbol?
Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."
How will Emergent Biosolutions' stock buyback program work?
Emergent Biosolutions declared that its Board of Directors has authorized a share buyback plan on Friday, March 23rd 2018, which permits the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.
How were Emergent Biosolutions' earnings last quarter?
Emergent Biosolutions Inc (NYSE:EBS) announced its quarterly earnings data on Thursday, November, 1st. The biopharmaceutical company reported $0.55 earnings per share for the quarter, missing analysts' consensus estimates of $0.62 by $0.07. The biopharmaceutical company earned $173.70 million during the quarter, compared to analyst estimates of $185.16 million. Emergent Biosolutions had a return on equity of 12.89% and a net margin of 14.19%. The business's revenue was up 16.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.73 EPS. View Emergent Biosolutions' Earnings History.
When is Emergent Biosolutions' next earnings date?
What guidance has Emergent Biosolutions issued on next quarter's earnings?
Emergent Biosolutions issued an update on its first quarter 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $185-205 million, compared to the consensus revenue estimate of $227.97 million.Emergent Biosolutions also updated its FY 2018 guidance to EPS.
What price target have analysts set for EBS?
7 brokers have issued 12-month price objectives for Emergent Biosolutions' stock. Their predictions range from $60.00 to $80.00. On average, they expect Emergent Biosolutions' stock price to reach $69.2857 in the next twelve months. This suggests a possible upside of 11.1% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.
What is the consensus analysts' recommendation for Emergent Biosolutions?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.
What are Wall Street analysts saying about Emergent Biosolutions stock?
Here are some recent quotes from research analysts about Emergent Biosolutions stock:
- 1. Cantor Fitzgerald analysts commented, "As investors appreciate the durability and revenue potential of Emergent’s portfolio, we expect upward earnings revisions and multiple expansion to drive the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $75. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and EV/EBITDA to get to our PT of $75." (1/4/2019)
- 2. According to Zacks Investment Research, "Emergent BioSolutions' recent acquisitions of PaxVax and Adapt Pharma look encouraging as they will expand the company’s presence in the public health threats market. We are positive on Emergent’s spin-off of its biosciences business into a separate publicly traded company as it resulted in reduction of the company’s cost structure. Shares of Emergent have outperformed the broader industry in 2018. Notably, the company derives majority of its revenues from BioThrax sales. Hence, its sole dependence on BioThrax for revenues is a headwind. Moreover, Emergent depends on certain single-source suppliers for key materials and services, which are necessary for manufacturing BioThrax. This in turn, also raises a concern." (1/3/2019)
Has Emergent Biosolutions been receiving favorable news coverage?
Press coverage about EBS stock has trended very positive this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Emergent Biosolutions earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
Who are some of Emergent Biosolutions' key competitors?
Some companies that are related to Emergent Biosolutions include Genmab A/S (GNMSF), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG) and Alkermes (ALKS).
Who are Emergent Biosolutions' key executives?
Emergent Biosolutions' management team includes the folowing people:
- Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
- Mr. Daniel J. Abdun-Nabi, CEO & Director (Age 64)
- Mr. Robert G. Kramer Sr., Pres & COO (Age 62)
- Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
- Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)
Who are Emergent Biosolutions' major shareholders?
Emergent Biosolutions' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.53%), Boston Advisors LLC (0.08%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.03%), Meeder Asset Management Inc. (0.02%) and Bowling Portfolio Management LLC (0.02%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.
Which institutional investors are selling Emergent Biosolutions stock?
EBS stock was sold by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Peregrine Capital Management LLC, Bowling Portfolio Management LLC, Louisiana State Employees Retirement System and Meeder Asset Management Inc.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Jerome M Hauer, Kathryn C Zoon, Ronald Richard and Sue Bailey. View Insider Buying and Selling for Emergent Biosolutions.
Which institutional investors are buying Emergent Biosolutions stock?
How do I buy shares of Emergent Biosolutions?
Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Emergent Biosolutions' stock price today?
One share of EBS stock can currently be purchased for approximately $62.34.
How big of a company is Emergent Biosolutions?
Emergent Biosolutions has a market capitalization of $3.18 billion and generates $560.87 million in revenue each year. The biopharmaceutical company earns $82.59 million in net income (profit) each year or $1.90 on an earnings per share basis. Emergent Biosolutions employs 1,256 workers across the globe.
What is Emergent Biosolutions' official website?
How can I contact Emergent Biosolutions?
Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]
MarketBeat Community Rating for Emergent Biosolutions (NYSE EBS)
MarketBeat's community ratings are surveys of what our community members think about Emergent Biosolutions and other stocks. Vote "Outperform" if you believe EBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EBS will underperform the S&P 500 over the long term. You may vote once every thirty days.
